What’s Next for GW Pharmaceuticals plc (GWPH) After Today’s Big Increase?

December 7, 2017 - By Henry Gaston

The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) is a huge mover today! The stock increased 7.73% or $8.97 during the last trading session, reaching $124.97. About 1.22M shares traded or 223.85% up from the average. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 31.90% since December 7, 2016 and is uptrending. It has outperformed by 15.20% the S&P500.
The move comes after 9 months positive chart setup for the $3.17 billion company. It was reported on Dec, 7 by Barchart.com. We have $131.22 PT which if reached, will make NASDAQ:GWPH worth $158.50 million more.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

Among 13 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. GW Pharmaceuticals had 22 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given on Monday, November 30 by TH Capital. Leerink Swann maintained GW Pharmaceuticals plc (NASDAQ:GWPH) rating on Monday, October 2. Leerink Swann has “Outperform” rating and $153 target. The firm earned “Sell” rating on Monday, June 27 by Janney Capital. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given on Thursday, October 26 by Cowen & Co. The firm has “Hold” rating by Numis Securities given on Friday, August 26. The rating was maintained by Maxim Group with “Buy” on Monday, August 7. The rating was maintained by Cantor Fitzgerald on Tuesday, August 8 with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, September 26. The firm has “Buy” rating by Piper Jaffray given on Thursday, August 3. As per Monday, December 5, the company rating was maintained by Cantor Fitzgerald.

More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Investorplace.com which released: “Get Long GW Pharmaceuticals PLC- ADR (GWPH) Stock for Free” on July 12, 2017, also Benzinga.com with their article: “Is GW Pharma Now The Future Of Cannabis-Based Drugs?” published on August 08, 2017, Investorplace.com published: “Get Long GW Pharmaceuticals PLC- ADR for Free” on December 04, 2017. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Investorplace.com and their article: “GW Pharmaceuticals PLC- ADR (GWPH) Stock Is High-Risk, High Reward” published on August 18, 2017 as well as Investorplace.com‘s news article titled: “GW Pharmaceuticals PLC- ADR (GWPH) Stock Is Just Getting Started” with publication date: December 06, 2016.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company has market cap of $3.17 billion. It operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development. It currently has negative earnings. The firm markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.